Feldman, Igor

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

Weber, J. S., Carlino, M. S., Khattak, A., Meniawy, T., Ansstas, G., Taylor, M. H., Kim, K. B., McKean, M., Long, G. V., Sullivan, R. J., et al. (2024) · The Lancet

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 916

An unbiased oncology compound screen to identify novel combination strategies

O'Neil, J., Benita, Y., Feldman, I., Chenard, M., Roberts, B., Liu, Y., Li, J., Kral, A., Lejnine, S., Loboda, A., et al. (2016) · Molecular Cancer Therapeutics

PI3K/AKT/mTOR signaling in cancerComputational Drug Discovery Methods

Cited by 407

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

Loboda, A., Nebozhyn, M., Klinghoffer, R., Frazier, J., Chastain, M., Arthur, W., Roberts, B., Zhang, T., Chenard, M., Haines, B., et al. (2010) · BMC Medical Genomics

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 152

T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study

Gainor, J. F., Patel, M. R., Weber, J. S., Gutierrez, M., Bauman, J. E., Clarke, J. M., Julian, R., Scott, A. J., Geiger, J. L., Kirtane, K., et al. (2024) · Cancer Discovery

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 124

EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL

Brach, D., Johnston-Blackwell, D., Drew, A., Lingaraj, T., Motwani, V., Warholic, N. M., Feldman, I., Plescia, C., Smith, J. J., Copeland, R. A., et al. (2017) · Molecular Cancer Therapeutics

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 70